LipiGesic M is the only recommended first-line therapy for acute migraine that has no evidence of rebound headache

SCHOFIELD, Wis., Aug. 5, 2013 /PRNewswire/ -- PuraMed BioScience^®, Inc., (OTCBB:PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, confirmed today that its product, LipiGesic^® M, a homeopathic formulation of feverfew and ginger that eliminates migraine pain and associated symptoms, is the only recommended first-line therapy for acute migraine in the retail market today that has shown no evidence of rebound or medication-overuse headache.

Rebound, or medication-overuse headaches typically result when a person suffering migraines takes an OTC pain reliever or prescription migraine medication more than twice a week. According to the American Headache Society, all acute treatments can produce a medication-over-use or rebound headache.

However, LipiGesic M is Not Associated With Rebound Headache.

In the article, Advances in Drug Development for Acute Migraine, published in Drugs medical journal in December 2012, the authors, including headache expert Dr. Roger Cady, said of LipiGesic M, "Advantages of this product include lower cost, OTC availability, and it is not likely to produce medication-overuse headache. It is an excellent first-line therapy for very early intervention, as it is compatible with all other acute treatment options."

"To my knowledge, there have been no reported incidences of LipiGesic M causing a rebound headache, no matter how frequently a person uses it to treat migraine pain," said Russ Mitchell, CEO of PuraMed BioScience. "Migraineurs who rely on the commonly used prescription migraine medications and over-the-counter migraine formulations run a high risk for rebound headache, but our product, LipiGesic M, has been shown to have none of those effects.

"With the widespread incidence of rebound headache associated with migraine medications, and the increased number of Food and Drug Administration warnings associated with acetaminophen, it is personally fulfilling to offer a treatment for acute migraine that works as well as the top-selling triptan products, but without increasing health risks," said Mitchell. "Having watched a loved one suffer with migraine pain, I am thankful that I'm able to provide consumers with a product that stops migraines fast without the risk of further harm."

When comparing LipiGesic M to a comprehensive list published by the Cleveland Clinic of both over-the-counter and prescription formulations for the treatment of acute migraine headaches, it stands alone as a viable migraine treatment without risk of rebound headache. The extensive list that was published on the Cleveland Clinic website includes: "aspirin, sinus relief medications, acetaminophen, nonsteroidal anti-inflammatory medications (NSAIDs), sedatives for sleep, codeine and prescription narcotics, and over-the-counter combination headache remedies containing caffeine (such as Anacin^®, Excedrin^®, Bayer Select^®, and others).

"Other medications commonly associated with rebound headaches are ergotamine preparations (Cafergot^®, Migergot^®, Ergomar^®, Bellergal-S^®, Bel-Phen-Ergot S^®, Phenerbel-S^®, Ercaf^®, Wigraine^® and Cafatine PB^®), butalbital combination analgesics (Goody's Headache Powder^®, Supac^®, Excedrin^®, Fiorinal^®) and opiates (codeine). The triptans – which are migraine-specific medications and include Imitrex^®, Zomig^®, Maxalt^®, Relpax^®, Axert^®, Frova^®, Amerge^®, and Treximet^® – taken more than 2 times per week can also cause rebound headaches." http://my.clevelandclinic.org/disorders/Headaches/hic_Rebound_Headaches.aspx

Medication-overuse headache is related to common OTC medications.

In the article, "Doctor Says Painkillers Cause Epidemic of Child Headaches," which was published on August 2, 2013 in the Herald Scotland, Dr. Ishaq Abu-Arafeh, who runs a headache clinic at the Royal Hospital for Sick Children in Yokhill, Glasgow, Scotland, states there has been an increase in children who are suffering from headaches because they are either consuming too much caffeine or too much paracetamol, which is known as acetaminophen in the U.S.

Dr. Abu-Arafeh explained, "prolonged use of paracetamol and ibuprofen can dull pain for a short time but makes the head more sensitive and more likely to feel sore."

In most cases, the only way for adults or children to stop the rebound effect is to stop taking the offending medication. This, however, should be done under a physician's care since it usually results in a severe withdrawal headache that may be accompanied by nausea, vomiting, restlessness, and disturbed sleep.

About LipiGesic M:
Results of a double-blind, placebo-controlled clinical trial for LipiGesic M show LipiGesic M is a highly effective treatment for acute migraine. The study was published in the July 2011 issue of the top-tier medical journal, Headache: The Journal of Head and Face Pain. LipiGesic M has national distribution and is available nationwide in Walgreens and CVS/pharmacy stores nationwide. In addition to LipiGesic M, the Company also has plans to launch LipiGesic H, tension headache remedy, as well as LipiGesic PM, a remedy for insomnia and other sleep disorders. www.lipigesic.com

As of August 01, 2013, the Company currently had around 43 million common shares issued and outstanding.

Forward-Looking Statements:
This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.

Contact:
PuraMed BioScience, Inc.
Russell Mitchell, Chairman and CEO
715-359-6373
[email protected]
www.PuramedBioScience.com

SOURCE PuraMed BioScience, Inc.